US Patent

US7737112 — Composition for enzyme inhibition

Formulation · Assigned to Onyx Therapeutics Inc · Expires 2027-12-07 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions that increase the solubility of proteasome inhibitors, such as those used in Kyprolis, for easier administration.

USPTO Abstract

Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US7737112
Jurisdiction
US
Classification
Formulation
Expires
2027-12-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Onyx Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.